Fe3O4@mSiO2 core–shell nanocomposite capped with disulfide gatekeepers for enzyme-sensitive controlled release of anti-cancer drugs

Yang, Chunyu; Guo, Wei; Cui, Liru; An, Na; Zhang, Ting; Guo, Gang; Lin, Huiming; Qu, Fengyu

doi:10.1039/c4tb01788a

Cited by 34 publications

(28 citation statements)

References 47 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro glutathione‐responsive release of DXM from SiO 2 NCs was studied by incubating purified nanocapsules in an aqueous medium containing 10 × 10 −3 m GSH, which is commonly used to mimic the reducing intracellular microenvironment. [ 18,48,49 ] The GSH‐responsive release mechanism is shown in Figure a.…”

Section: Resultsmentioning

confidence: 99%

Versatile Preparation of Silica Nanocapsules for Biomedical Applications

Jiang

Mottola

Han

et al. 2020

Part & Part Syst Charact

View full text Add to dashboard Cite

Core–shell nanocapsules are receiving increasing interest for drug delivery applications. Silica nanocapsules have been the focus of intensive studies due to their biocompatibility, versatile silica chemistry, and tunable porosity. However, a versatile one‐step preparation of silica nanocapsules with well‐defined core–shell structure, tunable size, flexible interior loading, and tailored shell composition, permeability, and surface functionalization for site‐specific drug release and therapeutic tracking remains a challenge. Herein, an interfacially confined sol–gel process in miniemulsion for the one‐step versatile preparation of functional silica nanocapsules is developed. Uniform nanocapsules with diameters from 60 to 400 nm are obtained and a large variety of hydrophobic liquids are encapsulated in the core. When solvents with low boiling point are loaded, subsequent solvent evaporation converts the initially hydrophobic cavity into an aqueous environment. Stimuli‐responsive permeability of nanocapsules is programmed by introducing disulfide or tetrasulfide bonds in the shell. Selective and sustained release of dexamethasone in response to glutathione tripeptide for over 10 d is achieved. Fluorescence labeling of the silica shell and magnetic loading in the internal cavity enable therapeutic tracking of nanocapsules by fluorescence and electron microscopies. Thus, silica nanocapsules represent a promising theranostic nanoplatform for targeted drug delivery applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Versatile Preparation of Silica Nanocapsules for Biomedical Applications

Jiang

Mottola

Han

et al. 2020

Part & Part Syst Charact

View full text Add to dashboard Cite

show abstract

“…The Fe 3 O 4 /SiO 2 core-shell NPs were fabricated using the modified Stöber method (Slowing et al., 2008; Yang et al., 2015). In this synthesis method, the organosilane precursor TEOS interacts with a positively charged CTAB template that assembles into tubular micelles in water.…”

Section: Resultsmentioning

confidence: 99%

Zinc oxide end-capped Fe₃O₄@mSiO₂core-shell nanocarriers as targeted and responsive drug delivery system for chemo-/ions synergistic therapeutics

et al. 2019

View full text Add to dashboard Cite

Multifunctional core-shell nanocarriers based on zinc oxide (ZnO)-gated magnetic mesoporous silica nanoparticles (MMSN) were prepared for cancer treatment through magnetic targeting and pH-triggered controlled drug release. Under an external magnetic field, the MMSN could actively deliver chemotherapeutic agent, daunomycin (DNM), to the targeted sites. At neutral aqueous, the functionalized MMSN could stably accommodate the DNM molecules since the mesopores were capped by the ZnO gatekeepers. In contrast, at the acid intercellular environment, the gatekeepers would be removed to control the release of drugs due to the dissolution of ZnO. Meanwhile, ZnO quantum dots not only rapidly dissolve in an acidic condition of cancer cells but also enhance the anti-cancer effect of Zn 2+ . An in vitro controlled release proliferation indicated that the acid sensitive ZnO gatekeepers showed well response by the ‘on-off’ switch of the pores. Cellular experiments against cervical cancer cell (HeLa cells) further showed that functionalized MMSN significantly suppressed cancer cells growth through synergistic effects between the chemotherapy and Zn 2+ ions with monitoring the treatment process. These results suggested that the ZnO-gated MMSN platform is a promising approach to serve as a pH-sensitive system for chemotherapies delivery and Zn 2+ controlled release for further application in the treatment of various cancers by synergistic effects.

show abstract

“…The average pore volume and pore diameter of MMSN were found to be 0.27 cm 3 /g and 3.2 nm, respectively. 37…”

Section: Resultsmentioning

confidence: 99%

Calcium carbonate end-capped, folate-mediated Fe₃O₄@mSiO₂ core-shell nanocarriers as targeted controlled-release drug delivery system

Liu

Chen

et al. 2018

J Biomater Appl

View full text Add to dashboard Cite

Magnetic mesoporous silica nanospheres (MMSN) were prepared and the surface was modified with cancer cell-specific ligand folic acid. Calcium carbonate was then employed as acid-activated gatekeepers to cap the mesopores of the MMSN, namely, MMSN-FA-CaCO. The formation of the MMSN-FA-CaCO was proved by several characterization techniques, viz. transmission electron microscopy, zeta potential measurement, Fourier transform infrared spectroscopy, BET surface area measurement, and UV-Vis spectroscopy. Daunomycin was successfully loaded in the MMSN-FA-CaCO and the system exhibited sensitive pH stimuli-responsive release characteristics under blood or tumor microenvironment. Cellular uptake by folate receptor (FR)-overexpressing HeLa cells of the MMSN-FA-CaCO was higher than that by non-folated-conjugated ones. Intracellular-uptake studies revealed preferential uptake of these nanoparticles into FR-positive [FR(+)] HeLa than FR-negative [FR(-)]A549 cell lines. DAPI stain experiment showed high apoptotic rate of MMSN-FA-DNM-CaCO to HeLa cells. The present data suggest that the CaCO coating and folic acid modification of MMSN are able to create a targeted, pH-sensitive template for drug delivery system with application in cancer therapy.

show abstract

Fe₃O₄@mSiO₂ core–shell nanocomposite capped with disulfide gatekeepers for enzyme-sensitive controlled release of anti-cancer drugs

Abstract: Multifunctional nanocarriers based on the magnetic Fe3O4 nanoparticle core and bis-(3-carboxy-4-hydroxy phenyl) disulfide modified mesoporous silica shell were synthesized for cancer treatment through passive targeting and enzyme-sensitive drug release.

Cited by 34 publications

References 47 publications

Versatile Preparation of Silica Nanocapsules for Biomedical Applications

Versatile Preparation of Silica Nanocapsules for Biomedical Applications

Zinc oxide end-capped Fe₃O₄@mSiO₂core-shell nanocarriers as targeted and responsive drug delivery system for chemo-/ions synergistic therapeutics

Calcium carbonate end-capped, folate-mediated Fe₃O₄@mSiO₂ core-shell nanocarriers as targeted controlled-release drug delivery system

Contact Info

Product

Resources

About

Fe3O4@mSiO2 core–shell nanocomposite capped with disulfide gatekeepers for enzyme-sensitive controlled release of anti-cancer drugs

Abstract: Multifunctional nanocarriers based on the magnetic Fe3O4 nanoparticle core and bis-(3-carboxy-4-hydroxy phenyl) disulfide modified mesoporous silica shell were synthesized for cancer treatment through passive targeting and enzyme-sensitive drug release.

Cited by 34 publications

References 47 publications

Versatile Preparation of Silica Nanocapsules for Biomedical Applications

Versatile Preparation of Silica Nanocapsules for Biomedical Applications

Zinc oxide end-capped Fe3O4@mSiO2core-shell nanocarriers as targeted and responsive drug delivery system for chemo-/ions synergistic therapeutics

Calcium carbonate end-capped, folate-mediated Fe3O4@mSiO2 core-shell nanocarriers as targeted controlled-release drug delivery system

Contact Info

Product

Resources

About

Fe₃O₄@mSiO₂ core–shell nanocomposite capped with disulfide gatekeepers for enzyme-sensitive controlled release of anti-cancer drugs

Zinc oxide end-capped Fe₃O₄@mSiO₂core-shell nanocarriers as targeted and responsive drug delivery system for chemo-/ions synergistic therapeutics

Calcium carbonate end-capped, folate-mediated Fe₃O₄@mSiO₂ core-shell nanocarriers as targeted controlled-release drug delivery system